Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Exelixis
Biotech
FDA delays approval verdict for Exelixis-Tecentriq combo
The three-month delay in the review period was coupled with the FDA asking for updated safety and efficacy data by March 2027.
Marissa Russo
Sep 11, 2026 9:52am
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
Jun 22, 2026 3:40pm
Merck inks Keytruda supply pact to support Exelixis cancer trial
May 19, 2026 9:38am
Midsize biotechs form coalition to fight against MFN policy
Feb 25, 2026 1:05pm
Fierce Pharma
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
ESMO: Exelixis' TKI reduces risk of death by 20%
Oct 20, 2025 2:30am
